Loading
Loading
Thymosin Beta-4 synthetic analogue · Systemic healing · G-actin sequestration
Sequesters G-actin to promote cell migration and proliferation at injury sites; downregulates inflammatory cytokines and upregulates anti-inflammatory mediators including interleukin-10.
Thymosin Beta-4 Fragment (TB-500) is a synthetic peptide derived from a naturally occurring protein known as Thymosin Beta-4, which has been widely studied in preclinical research for its potential role in cellular repair and regeneration processes. As a fragment-based analog, TB-500 is designed to mirror specific functional regions of the parent peptide, particularly those associated with cell migration, structural organization, and tissue remodeling. Research into TB-500 is conducted primarily in controlled laboratory and animal-based models, with a focus on understanding its biological activity at the cellular level.
Across experimental settings, TB-500 has been examined for its potential influence on mechanisms such as cell differentiation, angiogenesis, and cytoskeletal dynamics. Its interaction with actin—a key component of cellular structure—has been a central focus, as this relationship may play a role in how cells move, repair, and reorganize following injury in model systems. Researchers have also explored how TB-500 may affect signaling pathways involved in inflammation, tissue regeneration, and wound healing under preclinical conditions.
In addition to its structural and regenerative research focus, TB-500 has been evaluated for its potential involvement in recovery-related processes within experimental models. Studies have investigated its possible role in supporting cellular responses to stress, including oxidative stress and localized tissue disruption. These investigations often center on how the peptide may influence biological signaling cascades tied to repair efficiency and cellular resilience.
To support consistent experimental outcomes, TB-500 is synthesized and stabilized for laboratory use, enabling researchers to isolate and examine its functional properties under controlled conditions. All findings referenced are derived exclusively from non-clinical research. There are no established conclusions regarding human safety, pharmacokinetics, dosing, or therapeutic applications, and all observations remain within the scope of ongoing scientific investigation.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Listed as prohibited under WADA anti-doping regulations
Prescription availability in Australia and internationally
In Australia, tb-500 peptide has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
TB-500 Peptide research is most relevant to protocols examining:
Systemic tissue repair research
tendon, muscle, and cardiac injury models
Studies of G-actin sequestration and cytoskeletal remodelling in wound healing
Research examining anti-inflammatory cytokine modulation post-injury
Athletic recovery biology investigations requiring a systemic healing agent
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Measurable effects begin to establish. Mid-cycle assessment is appropriate at this point in well-designed protocols.
Peak activity window
Effects compound in this window. Given limited human data, careful documentation is important.
Washout & review
Allow full washout (~5× half-life: ~Hours to days). Review data, confirm baseline recovery before any repeat protocol.
Sequesters G-actin to promote cell migration and proliferation at injury sites; downregulates inflammatory cytokines and upregulates anti-inflammatory mediators including interleukin-10.
| Parameter | Value |
|---|---|
| Dose range | 5–10 mg/week (loading), 2–5 mg/week (maintenance) |
| Schedule | 2× per week (loading phase), weekly (maintenance) |
| Route | Subcutaneous, Intramuscular |
| Half-life | ~Hours to days |
Skipping the loading phase
Fix: 5–10 mg/week for the first 4 weeks is important for tissue levels
Not pairing with BPC-157 for complementary local/systemic coverage
Running continuously without washout
Fix: cycle 8–12 weeks then take a break
Using TB-500 as a substitute for physiotherapy rather than a complement
Community & Anecdotal Signal
Community signal is substantial and skews positive for injury recovery applications, though not as dramatically as BPC-157. Tendon and ligament injury reports are the dominant use case discussed, users frequently stack TB-500 with BPC-157 for what they call synergistic healing effects. Systemic vs localized injection debate is active, with many users preferring systemic administration based on TB-500's mechanism. Hair growth as a side effect is reported frequently enough to have its own community discussion thread on r/tressless and r/Peptides. Side effect reports are notably rare. The animal-
Anecdotal reports are not clinical evidence. Signal may reflect sourcing quality, dosing variation, and expectation bias.
Available from Capital Peptides
References
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.
